Title |
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
|
---|---|
Published in |
Clinical Pharmacology & Therapeutics, February 2017
|
DOI | 10.1002/cpt.597 |
Pubmed ID | |
Authors |
JK Hicks, K Sangkuhl, JJ Swen, VL Ellingrod, DJ Müller, K Shimoda, Bishop, ED Kharasch, TC Skaar, A Gaedigk, HM Dunnenberger, TE Klein, KE Caudle, JC Stingl |
Abstract |
CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimipramine). Evidence is presented for CYP2D6 and CYP2C19 genotype-directed dosing of TCAs. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. This article is protected by copyright. All rights reserved. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 2 | 33% |
United States | 1 | 17% |
Spain | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 33% |
Members of the public | 2 | 33% |
Scientists | 2 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | <1% |
Unknown | 357 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 43 | 12% |
Student > Ph. D. Student | 42 | 12% |
Researcher | 40 | 11% |
Student > Master | 37 | 10% |
Other | 30 | 8% |
Other | 57 | 16% |
Unknown | 109 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 65 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 63 | 18% |
Medicine and Dentistry | 62 | 17% |
Agricultural and Biological Sciences | 16 | 4% |
Neuroscience | 9 | 3% |
Other | 27 | 8% |
Unknown | 116 | 32% |